13.04.2022 Drägerwerk AG & Co. KGaA  DE0005550602

DGAP-Adhoc: Drägerwerk AG & Co. KGaA: Preliminary figures for the first quarter of 2022 - Increasing difficulties in the supply of electronic components make the lower end of the full-year guidance likely


 

DGAP-Ad-hoc: Drägerwerk AG & Co. KGaA / Key word(s): Preliminary Results/Forecast
Drägerwerk AG & Co. KGaA: Preliminary figures for the first quarter of 2022 - Increasing difficulties in the supply of electronic components make the lower end of the full-year guidance likely

13-Apr-2022 / 21:59 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Ad-hoc notification in accordance with Sec. 17 of the MAR

Drägerwerk AG & Co. KGaA: Dräger releases preliminary figures for the first quarter of 2022 - Increasing difficulties in the supply of electronic components make the lower end of the full-year guidance likely

Lübeck, April 13, 2022 - Based on preliminary calculations, Dräger's net sales in the first quarter of 2022 amounted to EUR 649.5 million (Q1 2021: EUR 792.1 million). Adjusted for currency effects, this was 19.5 percent below the record figure of the prior-year quarter. The main reason for this was the significantly lower demand for ventilators and respiratory protection masks, which had been strongly in demand until the end of last year in connection with the coronavirus pandemic. The resulting change in the product composition of net sales (mix effect) also resulted in a significantly lower gross profit margin of 42.2 percent (Q1 2021: 52.1 percent). In addition, sharply rising prices for intermediate products, such as electronic components, as well as unchanged high freight and logistics costs continued to weigh on earnings. EBIT in the first quarter of 2022 was around EUR -35 million (Q1 2021: EUR 128.9 million).

Order intake developed positively. Adjusted for currency effects, it increased by 10.2 percent to EUR 825.7 million (Q1 2021: EUR 739.8 million) in the first quarter of 2022, growing both in the Medical and Safety divisions.

Business performance in the first quarter is therefore in line with the previously published guidance, which expects a currency-adjusted decline in net sales of between -5.0 and -9.0 percent and an EBIT margin of between 1.0 and 4.0 percent for the current year. The Executive Board confirms the guidance, but now considers the lower end likely due to the increasing difficulties in the supply of electronic components.

The full results for the first three months of the fiscal year will be published on April 28, 2022.

Drägerwerk AG & Co. KGaA
Moislinger Allee 53-55
23558 Lübeck, Deutschland
www.draeger.com

Investor Relations:
Thomas Fischler
Tel. +49 451 882-2685
[email protected]

Corporate Communications:
Melanie Kamann
Tel. +49 451 882-3998
[email protected]

Disclaimer
This ad hoc report contains statements on the future development of Dräger Group. These forward-looking statements are based on the current expectations, presumptions, and forecasts of the Executive Board as well as the information available to date. They were compiled to the best of the company's knowledge. Dräger does not provide any warranty nor assume any responsibility for the future developments and results described above. These are dependent on a number of factors. They entail various risks and contingencies outside of the company's influence and are based on assumptions which could prove to be incorrect. Dräger does not assume any responsibility for updating the forward-looking statements contained in this report. This does not infringe any legal stipulations on the adjustment of forecasts. Please go to Investor Relations / Definitions of financial indicators at www.draeger.com for information on alternative performance measures used.


13-Apr-2022 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Drägerwerk AG & Co. KGaA
Moislinger Allee 53-55
23558 Lübeck
Germany
Phone: +49 (0)451 882-0
Fax: +49 (0)451 882-2080
E-mail: [email protected]
Internet: www.draeger.com
ISIN: DE0005550602, DE 000 555 063 6, DE 000 555 071 9
WKN: 555060, 555063 Vorzüge, 555071 Genussschein D
Indices: SDAX
Listed: Regulated Market in Berlin, Frankfurt (Prime Standard), Hamburg, Hanover; Regulated Unofficial Market in Stuttgart, Tradegate Exchange
EQS News ID: 1327855

 
End of Announcement DGAP News Service

1327855  13-Apr-2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1327855&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023
Umsatzerlöse1 2.572,26 2.595,01 2.780,82 3.406,78 3.328,42 3.045,23 3.375,50
EBITDA1,2 240,00 147,91 193,71 521,07 421,00 55,80 315,00
EBITDA-Marge3 9,33 5,70 6,97 15,30 12,65 1,83
EBIT1,4 155,74 62,65 66,58 396,60 271,68 -88,61 166,43
EBIT-Marge5 6,05 2,41 2,39 11,64 8,16 -2,91 4,93
Jahresüberschuss1 98,50 34,90 33,79 249,89 154,27 -63,64 111,99
Netto-Marge6 3,83 1,34 1,22 7,34 4,64 -2,09 3,32
Cashflow1,7 143,34 4,09 164,42 459,98 384,89 -144,23 189,68
Ergebnis je Aktie8 4,12 1,42 1,38 10,19 7,13 -3,41 5,86
Dividende8 0,40 0,13 0,13 0,13 0,13 0,13 0,13
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: -

INVESTOR-INFORMATIONEN
©boersengefluester.de
Drägerwerk ST
WKN Kurs in € Einschätzung Börsenwert in Mio. €
555060 41,500 Kaufen 791,01
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
7,35 17,05 0,43 11,30
KBV KCV KUV EV/EBITDA
0,57 4,10 0,23 3,37
Dividende '22 in € Dividende '23 in € Div.-Rendite '23
in %
Hauptversammlung
0,13 1,74 4,19 09.05.2025
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
30.04.2025 25.07.2024 29.10.2024 03.04.2025
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-3,60% -5,81% -7,16% -12,26%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Drägerwerk AG & Co. KGaA  ISIN: DE0005550602 können Sie bei EQS abrufen


Medtech , 555060 , DRW8 , XETR:DRW8